REFERENCES
2. Clarke R, Jones BC, Sevigny CM, Hilakivi-Clarke LA, Sengupta S. Experimental models of endocrine responsive breast cancer: strengths, limitations, and use. Cancer Drug Resist 2021;4:762-83.
3. Bai Z, Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim) 2009;342:133-49.
4. Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today 2016;21:1181-8.
5. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227-41.
6. Jordan VC. 50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened? Endocr Relat Cancer 2021;28:R11-30.
7. Robertson JF. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data. Br J Cancer 2001;85 Suppl 2:11-4.
8. Gaudet HM, Cheng SB, Christensen EM, Filardo EJ. The G-protein coupled estrogen receptor, GPER: the inside and inside-out story. Mol Cell Endocrinol 2015;418 Pt 3:207-19.
9. Zhang J, Zhou C, Jiang H, et al. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer. Cell Death Dis 2017;8:e2732.
10. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
11. Wang ZY, Yin L. Estrogen receptor alpha-36 (ER-α36): a new player in human breast cancer. Mol Cell Endocrinol 2015;418 Pt 3:193-206.
12. Cottu PH. [Systemic neoadjuvant therapy of luminal breast cancer in 2016]. Bull Cancer 2017;104:69-78.
13. André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013;19:3693-702.
14. Fan P, Jordan VC. New insights into acquired endocrine resistance of breast cancer. Cancer Drug Resist 2019;2:198-209.
15. Hyder T, Marti JLG, Nasrazadani A, Brufsky AM. Statins and endocrine resistance in breast cancer. Cancer Drug Resist 2021;4:356-64.
16. Miller TW, Hennessy BT, González-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
17. Bostner J, Karlsson E, Pandiyan MJ, et al. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013;137:397-406.
18. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 2011;127:407-16.
19. Spears M, Cunningham CA, Taylor KJ, et al. Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. J Pathol 2012;227:481-9.
20. Gudimchuk NB, McIntosh JR. Regulation of microtubule dynamics, mechanics and function through the growing tip. Nat Rev Mol Cell Biol 2021;22:777-95.
21. Di Bartolomeo M, Raimondi A, Cecchi F, et al. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori 2021;107:150-9.
22. Duly AMP, Kao FCL, Teo WS, Kavallaris M. βIII-tubulin gene regulation in health and disease. Front Cell Dev Biol 2022;10:851542.
23. Kanakkanthara A, Miller JH. βIII-tubulin overexpression in cancer: causes, consequences, and potential therapies. Biochim Biophys Acta Rev Cancer 2021;1876:188607.
24. Imran M, Saleem S, Chaudhuri A, Ali J, Baboota S. Docetaxel: an update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer. J Drug Deliv Sci Technol 2020;60:101959.
25. Raza F, Zafar H, You X, Khan A, Wu J, Ge L. Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers. J Mater Chem B 2019;7:7639-55.
26. Yu Y, Qiu L. Optimizing particle size of docetaxel-loaded micelles for enhanced treatment of oral epidermoid carcinoma. Nanomedicine 2016;12:1941-9.
27. Gao X, Zhang J, Huang Z, et al. Reducing interstitial fluid pressure and inhibiting pulmonary metastasis of breast cancer by gelatin modified cationic lipid nanoparticles. ACS Appl Mater Interf 2017;9:29457-68.
28. Iselt M, Holtei W, Hilgard P. The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity. Arzneimittelforschung 1989;39:747-9.
29. Volkova YA, Antonov YS, Komkov AV, et al. Access to steroidal pyridazines via modified thiohydrazides. RSC Adv 2016;6:42863-8.
30. Reid G, Hübner MR, Métivier R, et al. Cyclic, Proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Molecular Cell 2003;11:695-707.
31. Scherbakov AM, Lobanova YS, Shatskaya VA, Onopchenko OV, Gershtein ES, Krasil'nikov MA. Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells? Breast Cancer Res Treat 2006;100:1-11.
32. Mruk DD, Cheng CY. Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits. Spermatogenesis 2011;1:121-2.
33. Bogush TA, Maiak MA, Saprykina NS, et al. Experimental verification on the hypothesis about the possibility of molecular diagnostics of local tumor spread on the lewis lung carcinoma model. Moscow Univ Chem Bull 2021;76:248-52.
34. Bergemann N, Mundt C, Parzer P, et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005;73:357-66.
35. Hassan LS, Monson RS, Danielson KK. Oestradiol levels may differ between premenopausal women, ages 18-50, with type 1 diabetes and matched controls. Diabetes Metab Res Rev 2017;33:e2829.
36. Angsuwathana S, Tanmahasamut P, Rattanachaiyanont M, et al. Serum follicle stimulating hormone and estradiol in peri/postmenopausal women attending Siriraj Menopause Clinic: a retrospective study. J Med Assoc Thai 2006;89:1101-8.
37. Huitrón-Bravo G, Denova-Gutiérrez E, Talavera JO, et al. Levels of serum estradiol and lifestyle factors related with bone mineral density in premenopausal Mexican women: a cross-sectional analysis. BMC Musculoskelet Disord 2016;17:437.
38. Nardulli AM, Romine LE, Carpo C, Greene GL, Rainish B. Estrogen receptor affinity and location of consensus and imperfect estrogen response elements influence transcription activation of simplified promoters. Mol Endocrinol 1996;10:694-704.
39. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999;13:857-68.
40. Bobin-Dubigeon C, Campone M, Rossignol E, Salaun E, Amiand MB, Bard JM. New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients. Future Sci OA 2019;5:FSO374.
41. Woo HI, Lee SK, Kim J, et al. Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget 2017;8:100296-311.
42. Hassan F, Mohammed G, El-hiti GA, Alshanon A, Yousif E. Cytotoxic effects of tamoxifen in breast cancer cells. J Unexplored Med Data 2018;3:3.
43. Kuznetsov YV, Levina IS, Scherbakov AM, et al. New estrogen receptor antagonists. 3,20-Dihydroxy-19-norpregna-1, 3, 5(10)-trienes: synthesis, molecular modeling, and biological evaluation. Eur J Med Chem 2018;143:670-82.
44. Seeger H, Huober J, Wallwiener D, Mueck AO. Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. Horm Metab Res 2004;36:277-80.
45. Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H. Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC Cancer 2007;7:197.
46. Tsakalozou E, Eckman AM, Bae Y. Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int 2012;2012:832059.
47. Gupta S, Weston A, Bearrs J, et al. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis 2016;19:349-57.
48. Samadi N, Ghanbari P, Mohseni M, et al. Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells. J Cancer Res Ther 2014;10:715-21.
49. García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012;14:108-45.
50. Ali S, Rasool M, Chaoudhry H, et al. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation 2016;12:135-9.
51. Taylor SC, Berkelman T, Yadav G, Hammond M. A defined methodology for reliable quantification of Western blot data. Mol Biotechnol 2013;55:217-26.
52. Basappa B, Chumadathil Pookunoth B, Shinduvalli Kempasiddegowda M, Knchugarakoppal Subbegowda R, Lobie PE, Pandey V. Novel biphenyl amines inhibit oestrogen receptor (ER)-α in ER-positive mammary carcinoma cells. Molecules 2021;26:783.
53. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 2010;32:35-48.
54. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010;8:31.
55. Amaral CL, Freitas LB, Tamura RE, et al. S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells. BMC Cancer 2016;16:602.
56. Sekino Y, Han X, Kawaguchi T, et al. TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer. Int J Mol Sci 2019;20:3936.
57. Razi Soofiyani S, Mohammad Hoseini A, Mohammadi A, Khaze Shahgoli V, Baradaran B, Hejazi MS. siRNA-mediated silencing of CIP2A enhances docetaxel activity against PC-3 prostate cancer cells. Adv Pharm Bull 2017;7:637-43.
58. Razi Soofiyani S, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull 2013;3:249-55.
59. Majidi Zolbanin N, Jafari R, Majidi J, et al. Targeted Co-delivery of docetaxel and cMET siRNA for treatment of mucin1 overexpressing breast cancer cells. Adv Pharm Bull 2018;8:383-93.
60. Sale MJ, Balmanno K, Cook SJ. Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction. Cancer Drug Resist 2019;2:365-80.
61. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J 2010;277:2-21.
63. Llorens F, Miró FA, Casañas A, et al. Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death. Exp Cell Res 2004;299:15-26.
64. Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002;277:12710-7.
65. Chauvin L, Goupille C, Blanc C, et al. Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways. Biochim Biophys Acta 2016;1861:380-90.
66. Maahs L, Sanchez BE, Gupta N, et al. Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer. PLoS One 2019;14:e0222510.
67. De Donato M, Mariani M, Petrella L, et al. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012;227:1034-41.
68. Roque DM, Bellone S, Buza N, et al. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am J Obstet Gynecol 2013;209:62.e1-9.
69. Saussede-Aim J, Matera EL, Ferlini C, Dumontet C. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton 2009;66:378-88.
70. Terry S, Ploussard G, Allory Y, et al. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009;101:951-6.
71. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17:1726-37.
72. Lebok P, Öztürk M, Heilenkötter U, et al. High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer. Oncol Lett 2016;11:1987-94.
73. Pentheroudakis G, Batistatou A, Kalogeras KT, et al. Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 2011;127:179-93.
